Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page, an internal version update that does not modify study content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 replaces v3.2.0. The update appears to be a site version change and does not affect the study information.SummaryDifference0.1%

- Check28 days agoChange DetectedThe Notice about lapse in government funding and operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNo changes to core study content such as eligibility, outcomes, or treatment schedule were observed on the Study Details page for NCT02708641. The observed differences appear to be minor formatting/layout adjustments that do not affect the study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference4%

- Check78 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.